We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Medtronic plc (MDT) is a leading medical devices business with stocks listed in the US. It opened the day at US$130.07 after a previous close of US$130.25. During the day the price has varied from a low of USD129.33 to a high of USD130.91. The latest price was USD129.85 (25 minute delay). Medtronic is listed on the NYSE. All prices are listed in US Dollars.
How to buy shares in Medtronic
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Medtronic. Find the share by name or ticker symbol: MDT. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Medtronic reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Medtronic, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Medtronic. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- Medtronic key stats
- Compare share trading platforms
- Is Medtronic stock a buy or sell?
- Medtronic performance over time
- Can I short Medtronic shares?
- Is Medtronic suitable for ethical investing?
- Are Medtronic shares over-valued?
- Medtronic's financials
- How volatile are Medtronic shares?
- Does Medtronic pay a dividend?
- Have Medtronic shares ever split?
- Other common questions
Medtronic share priceUse our graph to track the performance of MDT stocks over time.
Medtronic shares at a glance
|52-week range||US$86.3189 - US$131.38|
|50-day moving average||US$119.6626|
|200-day moving average||US$114.624|
|Dividend yield||US$2.28 (1.78%)|
|Earnings per share (TTM)||US$2.259|
Compare share trading platforms to buy stock
Is it a good time to buy Medtronic stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Medtronic price performance over time
|1 week (2021-04-12)||6.62%|
|1 month (2021-03-23)||12.88%|
Is Medtronic under- or over-valued?
Valuing Medtronic stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Medtronic's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Medtronic's P/E ratio
Medtronic's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 58x. In other words, Medtronic shares trade at around 58x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Medtronic's PEG ratio
Medtronic's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.9216. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Medtronic's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Medtronic's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$6.3 billion (£4.6 billion).
The EBITDA is a measure of a Medtronic's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||US$27.9 billion|
|Operating margin TTM||13.67%|
|Gross profit TTM||US$19.6 billion|
|Return on assets TTM||2.51%|
|Return on equity TTM||5.97%|
|Market capitalisation||US$175.7 billion|
TTM: trailing 12 months
Shorting Medtronic shares
There are currently 7.9 million Medtronic shares held short by investors – that's known as Medtronic's "short interest". This figure is 5.6% up from 7.5 million last month.
There are a few different ways that this level of interest in shorting Medtronic shares can be evaluated.
Medtronic's "short interest ratio" (SIR)
Medtronic's "short interest ratio" (SIR) is the quantity of Medtronic shares currently shorted divided by the average quantity of Medtronic shares traded daily (recently around 4.7 million). Medtronic's SIR currently stands at 1.69. In other words for every 100,000 Medtronic shares traded daily on the market, roughly 1690 shares are currently held short.
However Medtronic's short interest can also be evaluated against the total number of Medtronic shares, or, against the total number of tradable Medtronic shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Medtronic's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Medtronic shares in existence, roughly 10 shares are currently held short) or 0.0059% of the tradable shares (for every 100,000 tradable Medtronic shares, roughly 6 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Medtronic.
Find out more about how you can short Medtronic stock.
Medtronic's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Medtronic.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Medtronic's total ESG risk score
Total ESG risk: 26.86
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Medtronic's overall score of 26.86 (as at 12/31/2018) is nothing to write home about – landing it in it in the 41st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Medtronic is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Medtronic's environmental score
Environmental score: 4.07/100
Medtronic's environmental score of 4.07 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Medtronic is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Medtronic's social score
Social score: 15.28/100
Medtronic's social score of 15.28 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Medtronic is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Medtronic's governance score
Governance score: 9/100
Medtronic's governance score puts it squarely in the 5th percentile of companies rated in the same sector. That could suggest that Medtronic is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Medtronic's controversy score
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Medtronic scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Medtronic hasn't always managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||26.86|
|Total ESG percentile||40.62|
|Environmental score percentile||5|
|Social score percentile||5|
|Governance score percentile||5|
|Level of controversy||3|
Medtronic share dividends
Dividend payout ratio: 66.1% of net profits
Recently Medtronic has paid out, on average, around 66.1% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.81% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Medtronic shareholders could enjoy a 1.81% return on their shares, in the form of dividend payments. In Medtronic's case, that would currently equate to about $2.28 per share.
Medtronic's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Medtronic's most recent dividend payout was on 15 April 2021. The latest dividend was paid out to all shareholders who bought their shares by 24 March 2021 (the "ex-dividend date").
Have Medtronic's shares ever split?
Medtronic's shares were split on a 2:1 basis on 26 September 1999. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Medtronic shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Medtronic shares which in turn could have impacted Medtronic's share price.
Medtronic share price volatility
Over the last 12 months, Medtronic's shares have ranged in value from as little as US$86.3189 up to US$131.38. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Medtronic's is 0.7711. This would suggest that Medtronic's shares are less volatile than average (for this exchange).
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group. The Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Minimally Invasive Therapies Group segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, hernia mechanical devices, mesh implants, and gynecology products; electrosurgical hardware and instruments, and mesh fixation devices; and gastrointestinal, inhalation therapy, and renal care solutions. The Restorative Therapies Group segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; colorectal surgeons; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Group segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Frequently asked questions
Ask an Expert